American Capital Advisory’s ResMed RMD Stock Holding History

American Capital Advisory’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.56K	Buy	8 +3	+60%	+$622	﹤0.01%	682
2026 Q1	$1.12K	Buy	5 +1	+25%	+$249	﹤0.01%	660
2025 Q4	$964	Buy	4 +1	+33%	+$256	﹤0.01%	608
2025 Q3	$822	Buy	3 +1	+50%	+$273	﹤0.01%	579
2025 Q2	$516	Hold	2	–	–	﹤0.01%	623
2025 Q1	$448	Buy	+2	New	+$467	﹤0.01%	533

Other funds holding RMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

American Capital Advisory's RMD Position: Q2 2026 in Review

American Capital Advisory increased its ResMed (RMD) stake by 60% in Q2 2026, buying an estimated $622 and bringing the position to 8 shares worth $1.56K. The position accounts for ﹤0.01% of the portfolio, ranked #682.

American Capital Advisory first reported a position in RMD in Q1 2025 and has held it in 6 quarters since. 888 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

American Capital Advisory held 8 shares of ResMed worth $1.56K as of Q2 2026.
American Capital Advisory bought 3 ResMed shares in Q2 2026, an estimated $622.
ResMed made up ﹤0.01% of American Capital Advisory's portfolio in Q2 2026, its #682 holding.
American Capital Advisory first reported a position in ResMed in Q1 2025 and has held it in 6 quarters since.
888 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.